Peptide Therapy After 65: Why Polypharmacy, Frailty and Kidney Function Shape Protocol Design
Adults over 65 are underrepresented in peptide research and often take several regular medications. This article explains why assessment, slower dose titration and closer monitoring are standard considerations in this age group.
By The Protocols Company Research Desk
Interest in peptide therapy is growing among adults in their late sixties and beyond, often because they want to protect muscle, mobility and independence. Yet this is the age group where the evidence base is thinnest and where individual variation is greatest. Most preclinical and early clinical peptide research has been conducted in younger animals or healthy adults, so extrapolating to a 70-year-old with several diagnoses requires care. Understanding why clinicians slow down in this setting helps patients and families ask better questions.
The evidence gap in older adults
Research suggests that the growth hormone axis changes gradually with age, a process sometimes called the somatopause. It is tempting to assume that a lower IGF-1 level in an older adult is simply a deficit to correct. In practice, the picture is more nuanced. Population studies have linked both very low and very high IGF-1 levels with adverse outcomes in later life, and the relationship between GH-axis signalling, longevity and cancer risk remains an active area of debate in the literature.
For many other peptides, such as those studied for tissue repair, the available data are largely preclinical. Older tissue heals differently, with slower cell turnover, reduced vascular supply and more cross-linked collagen. Findings from young animal models may therefore not translate directly.
In older adults, the absence of evidence is a reason for caution and monitoring, not a reason to assume a standard adult protocol will behave in the same way.
Polypharmacy and interaction review
Many adults over 65 take five or more regular medications. Common examples include antihypertensives, statins, anticoagulants, acid-suppressing drugs, diabetes medicines and sleep or nerve-pain treatments. Each can interact with a peptide protocol through a different route:
- Blood pressure and vascular effects, where fluid shifts or vasodilation may add to the action of existing antihypertensive medication.
- Glucose handling, where GH-axis peptides can alter insulin sensitivity and change the picture for people already taking glucose-lowering drugs.
- Bleeding tendency, where injection-site bruising matters more for anyone on anticoagulants or antiplatelet therapy.
- Sedation and balance, where overnight protocols combined with sleep medication may increase the risk of falls.
A full medication reconciliation, including over-the-counter products and supplements, is therefore a starting point rather than an optional extra. Our related articles on medication interactions cover several of these classes in more detail.
Kidney function, frailty and monitoring
Kidney function typically declines with age, and peptides are cleared through renal and enzymatic pathways. A serum creatinine within the laboratory reference range can overstate true filtration in someone with low muscle mass, which is why estimated GFR, and sometimes cystatin C, is reviewed. Liver function, haemoglobin, glucose markers and IGF-1 are commonly checked at baseline and repeated during a protocol.
Why frailty assessment matters
Chronological age is a poor guide on its own. Two people aged 72 can differ widely in strength, gait speed, nutrition and cognitive reserve. Simple measures such as grip strength, walking speed and a sit-to-stand test help clinicians judge resilience. They also provide an objective baseline against which any change can be tracked, so that decisions rest on measurement rather than impressions.
In practice, this often means a lower starting exposure, longer intervals between adjustments, shorter initial review periods and a lower threshold for pausing. Cardiovascular screening, a review of cancer history and attention to fluid retention are particularly important, since swelling and joint symptoms may be harder to separate from existing conditions.
Foundations still come first
For older adults, the largest gains in muscle and function usually come from adequate protein intake, resistance training, vitamin D status and good sleep. Peptide protocols, where appropriate at all, sit on top of these foundations rather than replacing them. Any prescription in the UAE must also be issued within the DHA-regulated framework, following a documented physician assessment.
If you're exploring peptide therapy after 65 as part of your protocol, our clinical team can review your case — take the 2-minute quiz at /find-my-stack or book a free consultation at /book.
